CANDEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Candex, and when can generic versions of Candex launch?
Candex is a drug marketed by Bayer Pharms and is included in two NDAs.
The generic ingredient in CANDEX is nystatin. There are eight drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the nystatin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Candex
A generic version of CANDEX was approved as nystatin by FOUGERA PHARMS on September 23rd, 1982.
Summary for CANDEX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 131 |
Patent Applications: | 2,921 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CANDEX at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for CANDEX
US Patents and Regulatory Information for CANDEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Pharms | CANDEX | nystatin | CREAM;TOPICAL | 061810-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bayer Pharms | CANDEX | nystatin | LOTION;TOPICAL | 050233-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |